China Next Generation Cancer Diagnostic Devices Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Next Generation Cancer Diagnostic Devices Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Next Generation Sequencing Market Performance (Volume)
  • 2.1.2 qPCR & Multiplexing Market Performance (Volume)
  • 2.1.3 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR) Market Performance (Volume)
  • 2.1.4 Protein Microarrays Market Performance (Volume)
  • 2.1.5 DNA Microarrays Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Next Generation Sequencing Market Performance (Value)
  • 2.1.2 qPCR & Multiplexing Market Performance (Value)
  • 2.1.3 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR) Market Performance (Value)
  • 2.1.4 Protein Microarrays Market Performance (Value)
  • 2.1.5 DNA Microarrays Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Biomarker Development Market Performance (Volume)
  • 3.1.2 CTC Analysis Market Performance (Volume)
  • 3.1.3 Proteomic Analysis Market Performance (Volume)
  • 3.1.4 Epigenetic Analysis Market Performance (Volume)
  • 3.1.5 Genetic Analysis Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Roche Holding Ltd.(Switzerland)
  • 4.1.1 Roche Holding Ltd.(Switzerland) Profiles
  • 4.1.2 Roche Holding Ltd.(Switzerland) Product Information
  • 4.1.3 Roche Holding Ltd.(Switzerland) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.1.4 Roche Holding Ltd.(Switzerland) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.2 Abbott Laboratories(US)
  • 4.2.1 Abbott Laboratories(US) Profiles
  • 4.2.2 Abbott Laboratories(US) Product Information
  • 4.2.3 Abbott Laboratories(US) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.2.4 Abbott Laboratories(US) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.3 Siemens Healthcare(Germany)
  • 4.3.1 Siemens Healthcare(Germany) Profiles
  • 4.3.2 Siemens Healthcare(Germany) Product Information
  • 4.3.3 Siemens Healthcare(Germany) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.3.4 Siemens Healthcare(Germany) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.4 Agilent Technologies Inc(Germany)
  • 4.4.1 Agilent Technologies Inc(Germany) Profiles
  • 4.4.2 Agilent Technologies Inc(Germany) Product Information
  • 4.4.3 Agilent Technologies Inc(Germany) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.4.4 Agilent Technologies Inc(Germany) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.5 Illumina Inc.(US)
  • 4.5.1 Illumina Inc.(US) Profiles
  • 4.5.2 Illumina Inc.(US) Product Information
  • 4.5.3 Illumina Inc.(US) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.5.4 Illumina Inc.(US) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.6 Becton Dickinson and Co.(US)
  • 4.6.1 Becton Dickinson and Co.(US) Profiles
  • 4.6.2 Becton Dickinson and Co.(US) Product Information
  • 4.6.3 Becton Dickinson and Co.(US) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.6.4 Becton Dickinson and Co.(US) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.7 QIAGEN N.V.(Germany)
  • 4.7.1 QIAGEN N.V.(Germany) Profiles
  • 4.7.2 QIAGEN N.V.(Germany) Product Information
  • 4.7.3 QIAGEN N.V.(Germany) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.7.4 QIAGEN N.V.(Germany) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.8 Affymetrix Inc.(US)
  • 4.8.1 Affymetrix Inc.(US) Profiles
  • 4.8.2 Affymetrix Inc.(US) Product Information
  • 4.8.3 Affymetrix Inc.(US) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.8.4 Affymetrix Inc.(US) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.9 Johnson & Johnson(US)
  • 4.9.1 Johnson & Johnson(US) Profiles
  • 4.9.2 Johnson & Johnson(US) Product Information
  • 4.9.3 Johnson & Johnson(US) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.9.4 Johnson & Johnson(US) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.10 Thermo Fisher Scientific Inc.(US)
  • 4.10.1 Thermo Fisher Scientific Inc.(US) Profiles
  • 4.10.2 Thermo Fisher Scientific Inc.(US) Product Information
  • 4.10.3 Thermo Fisher Scientific Inc.(US) Next Generation Cancer Diagnostic Devices Business Performance
  • 4.10.4 Thermo Fisher Scientific Inc.(US) Next Generation Cancer Diagnostic Devices Business Development and Market Status
• 4.11 GE Healthcare(England)
• 4.12 Life Technologies Corp.(US)
• 4.13 Siemens Healthcare(Germany)
• 4.14 Agilent Technologies Inc(Germany)
• 4.15 Illumina Inc.(US)

5 Market Performance for Manufacturers

• 5.1 China Next Generation Cancer Diagnostic Devices Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 South China Market Performance for Manufacturers
  • 6.1.1 South China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 South China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 South China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 South China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 East China Market Performance for Manufacturers
  • 6.2.1 East China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 East China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 East China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 East China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 Southwest China Market Performance for Manufacturers
  • 6.3.1 Southwest China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 Southwest China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 Southwest China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 Southwest China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Northeast China Market Performance for Manufacturers
  • 6.4.1 Northeast China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Northeast China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Northeast China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Northeast China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 North China Market Performance for Manufacturers
  • 6.5.1 North China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 North China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 North China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 North China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Central China Market Performance for Manufacturers
  • 6.6.1 Central China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Central China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Central China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Central China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Northwest China Market Performance for Manufacturers
  • 6.7.1 Northwest China Next Generation Cancer Diagnostic Devices Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Northwest China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Northwest China Next Generation Cancer Diagnostic Devices Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Northwest China Next Generation Cancer Diagnostic Devices Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration

7 China Next Generation Cancer Diagnostic Devices Market Performance (Sales Point)

• 7.1 China Next Generation Cancer Diagnostic Devices Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 China Next Generation Cancer Diagnostic Devices Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 China Next Generation Cancer Diagnostic Devices Price (USD/Unit) by Regions 2013-2018
• 7.4 China Next Generation Cancer Diagnostic Devices Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 South China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 East China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 Southwest China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Northeast China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 North China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Central China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Northwest China Next Generation Cancer Diagnostic Devices Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Biomarker Development Industry
• 11.2 CTC Analysis Industry
• 11.3 Proteomic Analysis Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 China Next Generation Cancer Diagnostic Devices Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 South China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 East China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 Southwest China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Northeast China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 North China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Central China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Northwest China Next Generation Cancer Diagnostic Devices Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Next Generation Sequencing Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 qPCR & Multiplexing Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Protein Microarrays Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Biomarker Development Sales and and Growth Rate 2019-2024
  • 12.4.3 CTC Analysis Sales and and Growth Rate 2019-2024
  • 12.4.4 Proteomic Analysis Sales and and Growth Rate 2019-2024
  • 12.4.5 Epigenetic Analysis Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 China Next Generation Cancer Diagnostic Devices Price (USD/Unit) Trend 2019-2024
  • 12.5.2 China Next Generation Cancer Diagnostic Devices Gross Profit Trend 2019-2024

13 Conclusion